You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEW YORK (GenomeWeb News) – CombiMatrix increased the number of securities it intends to sell in a public offering, the company said today in a document filed with the US Securities and Exchange Commission.
NEW YORK (GenomeWeb News) – Response Genetics has launched a public offering of nearly 4.5 million shares of its common stock at $1.20 per share.
NEW YORK (GenomeWeb News) – CombiMatrix today raised the expected net proceeds from an intended public offering of its securities.
NEW YORK (GenomeWeb News) – CombiMatrix said today that it anticipates up to $10.4 million in net proceeds from a public offering of its securities.
NEW YORK (GenomeWeb News) – Atossa Genetics has filed a shelf registration to potentially offer from time to time up to $40 million in securities.
NEW YORK (GenomeWeb News) – Accelerate Diagnostics has filed a shelf registration to publicly offer from time to time up to $150 million of securities.
Tekmira Pharmaceuticals this week announced that it has completed the public offering of $30 million of its common stock.
NEW YORK (GenomeWeb News) – Venaxis, which is developing a multi-biomarker test for appendicitis, filed a shelf registration to publicly offer up to $20 million of its stock.
NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market last night that it had priced its offering of 2,858,000 shares of common stock at $14 per share.
NEW YORK (GenomeWeb News) – Cancer Genetics today increased the proposed amount it is seeking to raise from a public offering of its common stock.
Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.
US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.
The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.
In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.